Status message

Active context: kki_bg_colors_yellow

A Phase 2, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)

Principal Investigator:
Robert
Findling

A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)

To evaluate the safety and tolerability of SPD489, administered as a daily morning dose (5, 10, 15, 20, and 30mg/day) in the treatment of preschool children (4-5 years of age inclusive at the time of consent) with attention-deficit/hyperactivity disorder (ADHD).

Publications

Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.